Moderna mRNA vaccine almost halves the risk of skin cancer returning
Long-awaited results from phase III trial show a huge benefit in treating treatment-resistant melanoma.
Long-awaited results from phase III trial show a huge benefit in treating treatment-resistant melanoma.